CXCR1 and breast carcinoma: In breast cancer, the crosstalk with CAFs through PDGF-CC is a main determinant of the molecular subtype and blocking PDGF-CC is sufficient to revert basal-like resistant tumors into an ERα-positive subtype that responds to endocrine therapies [93].